ACKR3 and pulmonary fibrosis: Given the already recognized influence of CXCR7-agonist in ameliorating pulmonary fibrosis [104], its recently discovered efficacy in governing thrombo-inflammatory platelet-leukocyte interactions, and its regulation on the generation of thrombo-inflammatory lipids (e.g., TxA2, 12-HETE) [76], the anti-platelet significance of ACKR3/CXCR7 deserves a closer look in chronic and acute pulmonary inflammation.